Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 2, 2010, Pages 887-895

  Mou, Jiajia ^a   Fang, Hao ^a   Liu, Yingzi ^a,b   Shang, Luqing ^a   Wang, Qiang ^a   Zhang, Lei ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG POLICE COLLEGE   (China)

Author keywords

Amino peptidase N; Inhibitor; l Arginine; Metalloproteinase 2; Peptide analogue; Synthesis

Indexed keywords

2 (2 (2 AMINO 3 PHENYLPROPANAMIDO) 3 METHYLBUTANAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2 (2 (2 AMINO 3 PHENYLPROPANAMIDO) 4 METHYLPENTANAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2 (2 (2 AMINO 4 METHYLPENTANAMIDO)ACETAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2 (2 (2 AMINO 4 METHYLPENTANAMIDO)PROPANAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2 (2 AMINO 3 METHYLBUTANAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2 (2 AMINO 4 (METHYLTHIO)BUTANAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2 (2 AMINO 4 METHYLBUTANAMIDO) N HYDROXY 5 (3 NITROGUANIDINO)PENTANAMIDE; 2,4 DICHLORO N (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 1 OXO 3 PHENYLPROPAN 2 YL)BENZAMIDE; ANTINEOPLASTIC AGENT; ARGININE; BESTATIN; METHYL 2 (2 (2 (TERT BUTOXYCARBONYL) 4 METHYLPENTANAMIDO)ACETAMIDO) 5 (3 NITROGUANIDINO)PENTANOATE; METHYL 2 (2 (TERT BUTOXYCARBONYL) 3 METHYLBUTANAMIDO) 5 (3 NITROGUANIDINO)PENTANOATE; MICROSOMAL AMINOPEPTIDASE; N (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 1 OXO 3 PHENYLPROPAN 2 YL)BENZAMIDE; N (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 1 OXO 3 PHENYLPROPAN 2 YL)PYRROLIDINE; N (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 3 (4 HYDROXYPHENYL) 1 OXOPROPAN 2 YL)PYRROLIDINE 2 CARBOXAMIDE; N (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YL) 1 (PYRROLIDINE 2 CARBONYL)PYRROLIDINE 2 CARBOXAMIDE; TERT BUTYL 1 (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 1 OXOPROPAN 2 YLAMINO) 4 METHYL 1 OXOPENTAN 2 YLCARBAMATE; TERT BUTYL 1 (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 3 METHYL 1 OXOBUTAN 2 YLAMINO) 1 OXO 3 PHENYLPROPAN 2 YLCARBAMATE; TERT BUTYL 1 (1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 4 METHYL 1 OXOPENTAN 2 YLAMINO) 1 OXO 3 PHENYLPROPAN 2 YLCARBAMATE; TERT BUTYL 1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 3 METHYL 1 OXOBUTAN 2 YLCARBAMATE; TERT BUTYL 1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 4 (METHYLTHIO) 1 OXOBUTAN 2 YLCARBAMATE; TERT BUTYL 1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 4 METHYL 1 OXOPENTAN 2 YLCARBAMATE; TERT BUTYL 1 (2 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 2 OXOETHYLAMINO) 4 METHYL 1 OXOPENTAN 2 YLCARBAMATE; TERT BUTYL 2 ((1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 1 OXO 3 PHENYLPROPAN 2 YL)CARBAMOYL)PYRROLIDINE 1 CARBOXYLATE; TERT BUTYL 2 ((1 (1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YLAMINO) 3 (4 HYDROXYPHENYL) 1 OXOPROPAN 2 YL)CARBAMOYL)PYRROLIDINE 1 CARBOXYLATE; TERT BUTYL 2 (2 ((1 (HYDROXYAMINO) 5 (3 NITROGUANIDINO) 1 OXOPENTAN 2 YL)CARBAMOYL)PYRROLIDINE 1 CARBONYL)PYRROLIDINE 1 CARBOXYLATE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTIGENS, CD13; ARGININE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; MATRIX METALLOPROTEINASE 2; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 76449116522     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.11.036     Document Type: Article

References (13)

1. Bank U., Bohr U.R., Reinhold D., Lendeckel U., Ansorge S., Malfertheiner P., and Tager M. Front. Biosci. 13 (2008) 3699
2. Yamashita M., Kajiyama H., Terauchi M., Shibata K., Ino K., Nawa A., Mizutani S., and Kikkawa F. Int. J. Cancer 120 (2007) 2243
3. Shimizu T., Tani K., Hase K., Ogawa H., Huang L., Shinomiya F., and Sone S. Arthritis Rheum. 46 (2002) 2330
4. Reinhold D., Bank U., Täer M., Ansorge S., Wrenger S., Thielitz A., Lendeckel U., Faust J., Neubert K., and Brocke S. Front. Biosci. 13 (2008) 2356
5. Rahbar A., Boströ L., and Söerberg-Naucler C. J. Autoimmun. 26 (2006) 155
6. Xu W.F., and Li Q.B. Curr. Med. Chem. Anti-Cancer Agents 5 (2005) 281
7. Babine R.E., and Bender S.L. Chem. Rev. 97 (1997) 1359
8. Leung D., Abbenante G., and Fairlie D.P. J. Med. Chem. 43 (2000) 305
9. Shimazawa R., Takayama H., Hashimoto Y., et al. J. Enzyme Inhib. 14 (1999) 259
10. Ito K., Nakajima Y., Yoshimoto T., et al. J. Biol. Chem. 281 (2006) 33664
11. Mou J.J., Fang H., Jing F.B., Wang Q., Liu Y.Z., Xu W.F., et al. Bioorg. Med. Chem. 17 (2009) 4666
12. Haaina G., Lohse A., and Buchardt O. Angew. Chem., Int. Ed. Engl. 35 (1995) 1939
13. Jordis U., Sauter F., and Siddiqi S.M. Indian J. Chem. Sec. B (1989) 294